The controversial anti-malarial drug hydroxychloroquine (HCQ) is making headlines again. The World Health Organisation (WHO) on Wednesday said that it will resume the solidarity trial of HCQ for the potential treatment of coronavirus disease. A few days back the Organisation had implemented a temporary pause of the WHO-backed HCQ trials after a large-scale study flagged that the drug could cause more fatalities among COVID-19 patients. The study was published in the Lancet medical journal on May 22. More than two months back the WHO had initiated the Solidarity Trial to evaluate the safety and efficacy of four drugs and drug